Mark A. Gerhardt
Ohio State University
19 Papers
215 Citations
Mark A. Gerhardt is an academic researcher from Ohio State University. The author has contributed to research in topics: Heart failure & Sedation. The author has an hindex of 11, co-authored 19 publications.
Chat about Author
Papers
Dexmedetomidine for conscious sedation in difficult awake fiberoptic intubation cases
Sergio D. Bergese,Babak Khabiri,William D. Roberts,Michael B. Howie,Thomas D. McSweeney,Mark A. Gerhardt +5 more
TL;DR: Dexmedetomidine was used to provide a moderate level of conscious sedation without causing respiratory distress or hemodynamic instability during fiberoptic intubation on 4 patients with particularly difficult airways who underwent successful awake Fiberoptic Intubation with DEX.
106
“Dexmedetomidine for conscious sedation in difficult awake fiberoptic intubation cases, ” (J Clin Anesth 2007;19:141-4).
Sergio D. Bergese,Babak Khabiri,William D. Roberts,Michael B. Howie,Thomas D. McSweeney,Mark A. Gerhardt +5 more
TL;DR: Dexmedetomidine was used to provide a moderate level of conscious sedation without causing respiratory distress or hemodynamic instability during fiberoptic intubation on 4 patients with particularly difficult airways who underwent successful awake Fiberoptic Intubation with DEX.
102
Cytoskeletal remodeling of desmin is a more accurate measure of cardiac dysfunction than fibrosis or myocyte hypertrophy
Gretel Monreal,Lisa Nicholson,Bing Han,Mandar S. Joshi,Alistair Phillips,Loren E. Wold,Loren E. Wold,John Anthony Bauer,John Anthony Bauer,Mark A. Gerhardt +9 more
TL;DR: In this article, the cytoskeletal protein desmin was found to be a better predictor of heart failure than fibrosis or myocyte hypertrophy, suggesting that intra-myocyte responses, likely related to mechanical stretch, are better predictors of LV function and may represent novel targets for therapeutic intervention.
45
Selective microembolization of the circumflex coronary artery in an ovine model: dilated, ischemic cardiomyopathy and left ventricular dysfunction
Gretel Monreal,Mark A. Gerhardt,Atsushi Kambara,A. Reza Abrishamchian,John Anthony Bauer,Andrew H. Goldstein +5 more
TL;DR: This model of ventricular remodeling secondary to microinfarction, which continues to progress for up to 2 years despite stabilization of left ventricular ejection fraction, may be a useful experimental platform for large animal heart failure investigations.
34
Partial support with a centrifugal left ventricular assist device reduces myocardial oxygen consumption in chronic, ischemic heart failure.
Andrew H. Goldstein,Gretel Monreal,Atsushi Kambara,Allison J Spiwak,Matthew L. Schlossberg,A. Reza Abrishamchian,Mark A. Gerhardt +6 more
TL;DR: Complete support with a centrifugal LVAD is not necessary for achieving significant reductions in LVVO2 in CHF through comparatively minor reductions in cardiac work, which is the first study to examine partial LVAD support in a CHF model
33